Pharma Faces: Demet Russ, Janssen Turkey
After an international career spanning 25 years, Demet Russ returned to her native Turkey to lead the Janssen affiliate during a tumultuous time and is aiming to give back to…
UCB, a biopharmaceutical company, focuses on the discovery and development of medicines and solutions for people living with severe diseases of the immune system or of the central nervous system in Belgium and internationally. The company’s core products include Cimzia for Crohn’s disease, rheumatoid arthritis, psoriatic arthritis, and axial spondyloarthritis/ankylosing spondylitis; Vimpat for the treatment of epilepsy partial-onset seizures (POS); and Neupro for Parkinson’s disease and restless legs syndrome. It also offers Keppra for epilepsy POS, epilepsy primary generalized tonic-clonic seizures (PGTCS), and epilepsy myoclonic seizures; Zyrtec and Xyzal for allergy; Metadate for attention deficit and hyperactivity disorders; Nootropil for the treatment of psycho-organic syndromes or cognitive decline and cortical myoclonus; and Xyrem for narcolepsy with cataplexy in adult patients. In addition, the company provides Tussionex for relief of cough and upper respiratory symptoms associated with allergy or a cold; and Lortab for the relief from pain. UCB S.A. was founded in 1928 and is headquartered in Brussels, Belgium.
UCB products have been on the Turkish market since 1960, through the Turkish distributor Bilim. After 30 years, UCB Turkey was founded in 1990 with operations beginning in 1992.
Contact Details
Palladium Tower, Barbaros Mah.
Kardelen Sokak , No:2 Kat:24/80
34746 Ataşehir, İstanbul
Tel: +90 216 538 0000
Fax: +90 216 538 0009
E-mail: tr-bilgi@ucb.com
Website: www.ucb.com.tr
After an international career spanning 25 years, Demet Russ returned to her native Turkey to lead the Janssen affiliate during a tumultuous time and is aiming to give back to…
Avinash Potnis of Novartis Turkey discusses potential solutions to the country’s access and pricing dilemma which has raised concerns of system sustainability. Potnis also highlights the strengths of Turkey’s healthcare…
Ingrid Drechsel, head of Bayer’s pharma operations in Turkey and Iran, discusses the complexity of managing two countries under economic pressure and the advantages of Bayer’s longstanding relationship in both…
Menarini’s general manager for Turkey, the Middle East and Africa Uğur Bingöl discusses the Italian company’s restructuring in the region and its desire to replicate its success in Turkey across…
The secretary general for Turkey’s Pharmaceutical Manufacturers Association (IEIS), Savaş Malkoç, highlights their objective of increasing R&D expenditure and Turkey’s big opportunity ahead in biosimilars production. In addition, Malkoç discusses…
Janssen’s Managing Director for Turkey, Demet Russ, discusses her return to the country after 25 years abroad, having worked for Johnson & Johnson in different local, regional and global roles…
As one of the leading pharma companies in Turkey, DEVA is pioneering a new approach to generics in the country. Chairman of the Board and CEO Philipp Haas discusses the…
As COVID-19 began spreading through the world, the race to understand the disease by scientists and doctors took off. After just a few months, it became apparent that people with…
The president of the Turkish Society of Cardiology, Mustafa Kemal Erol, discusses the prevalence of cardiovascular disease, which accounts for over a third of deaths in Turkey, the improvements made…
AmCham Turkey’s executive director, Asli Özelli, examines the impact of US companies on the Turkish economy with over USD 50 billion in investment, their help during the pandemic, the chamber’s…
Dr Burak Cem, Novo Nordisk Vice President and General Manager for Turkey, outlines the company’s big bet on Turkey as a future regional hub through deep investment in clinical trials,…
Turkey’s former Minister of Health, Bülent Akarcali, outlines the country’s healthcare system evolution over the past decades, comparing the improvements to the difference between a Ford Model T to a…
See our Cookie Privacy Policy Here
